Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 8/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291337 | 1.00 | KMT2A (0.47) | KMT2ARIPK3MAPK14MAPK13MAPK12 | |
| SCHEMBL6291378 | 0.96 | RIPK3 (0.44) | KMT2ARIPK3MAPK14MAPK13MAPK12 | |
| SCHEMBL6294031 | 0.90 | KMT2A (0.42) | KMT2ARIPK3MAPK14 | |
| SCHEMBL27492751 | 0.84 | KMT2A (0.47) | KMT2ARIPK3MAPK14MAPK13MAPK12 | |
| SCHEMBL6476070 | 0.83 | PTGS2 (0.58) | KMT2AMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL6486568 | 0.81 | KMT2A (0.44) | KMT2ARIPK3 | |
| SCHEMBL6290029 | 0.81 | KMT2A (0.47) | KMT2ARIPK3MAPK14MAPK13MAPK12 | |
| SCHEMBL6291350 | 0.81 | KMT2A (0.47) | KMT2ARIPK3MAPK14MAPK13MAPK12 | |
| SCHEMBL6487001 | 0.81 | PTGS2 (0.60) | KMT2ARIPK3 | |
| SCHEMBL6294032 | 0.80 | KMT2A (0.38) | KMT2ARIPK3MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252163-B1 | 4-PYRIDYL-AND 2,4-PYRIMIDINYL-SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE IN PHARMACY | MERCKLE GMBH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20030153558-A1 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | MERCKLE GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153558-A1 | 4-Pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy | IL4, IL2, IL5 | KMT2A 4671/4885RIPK3 2758/4885MAPK14 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.